

1 ***Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A*** 2 ***practical review and meta-analysis***

3 Masoud Etemadifar^a; Hosein Nouri^{a,b}; Maristella Pitzalis^c; Maria Laura Idda^c; Mehri Salari^d; Mahshid
4 Baratian^e; Sepide Mahdavi^e; Amir Parsa Abhari^{a,b}; Nahad Sedaghat^{a,b*}.

5 a) Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan Multiple Sclerosis Center,
6 Isfahan Multiple Sclerosis Society, Isfahan, Iran.

7 b) Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific
8 Education and Research Network (USERN), Isfahan, Iran.

9 c) Institute for Genetic and Biomedical Research (IRGB) of National Research Council (CNR),
10 Cagliari, Italy.

11 d) Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical
12 Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

13 e) Clinical Research Development Center, Islamic Azad University of Najafabad, Isfahan, Iran.

14 **Corresponding Author:*

15 Nahad Sedaghat

16 Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan Multiple Sclerosis Center, Isfahan
17 Multiple Sclerosis Society, Isfahan, Iran.

18 Email: nahad.sedahat@gmail.com

19 ORCID: 0000-0002-2796-6791

20 Manuscript Details:

21 - Abstract word count: 382

22 - Main text word count: 3414

23 - Number of tables: 2

24 - Number of figures: 2

25 - Number of references: 85

26 - Number of supplementary files: 2

27 **Abstract**

28 **Importance:** An evidence-based appraisal of the COVID-19 vaccination policies among people with
29 multiple sclerosis (pwMS) with respect to disease-modifying therapies (DMT) is important for our
30 understandings and their further management.

31 **Objective:** To synthesize the available evidence concerning the effect of DMTs on COVID-19 vaccination
32 immunogenicity and effectiveness.

33 **Data Sources:** We searched MEDLINE, Scopus, Web of Science, MedRxiv, and Google Scholar from
34 January 2021 until January 2022.

35 **Study Selection:** The exclusion criteria included: not a primary investigation; retracted/withdrawn; no
36 eligible participants – people with no history/evidence of previous COVID-19 and corticosteroid
37 administration within two months of vaccination; no eligible exposures – all nine DMT classes; and no
38 eligible comparators – DMT-unexposed at the time of vaccination.

39 **Data Extraction and Synthesis:** Entries were assessed independently by two reviewers for eligibility and
40 quality. Dichotomized data was extracted by two reviewers in accordance with Cochrane guidelines, and
41 were pooled using either Peto fixed-effects or Inverse-variance random-effects methods.

42 **Main Outcomes and Measures:** Main outcomes were i) B-cell response, measured by seroconversion
43 odds ratio (OR); ii) T-cell response, measured by interferon-gamma release response OR, and
44 CD4+/CD8+ activation-induced marker+ OR. Further outcomes including immunity waning speed and
45 breakthrough COVID-19 incidence/severity were synthesized narratively.

46 **Results:** Data from 28 studies (5,025 pwMS and 1,635 healthy participants) after COVID-19 vaccination
47 suggests mildly-lower B-cell responses in teriflunomide- and alemtuzumab-treated, extensively-lower B-
48 cell responses in sphingosine-1-phosphate receptor modulator (S1PRM)- and anti-CD20 (aCD20)-treated,
49 and lower T-cell responses in interferon-, S1PRM-, alemtuzumab- and cladribine-treated pwMS. Every
50 ten-week increase in aCD20-to-vaccine period is associated with a 1.94-time (95%CI: 1.57, 2.41,
51 $P < 0.00001$) increase in odds of seroconversion. B-cell-depleting therapies seem to accelerate post-
52 vaccination humoral waning, and booster immunogenicity is predictable with the same factors affecting
53 the priming vaccination. Furthermore, comparatively-increased breakthrough COVID-19 incidence and
54 severity is being observed only among S1PRM- and anti-CD20-treated pwMS – i.e., among the pwMS
55 with extensively-blunted B-cell response, despite adequate T-cell responses in the aCD20-treated. To
56 date, pwMS on only-T-cell-blunting DMTs have not shown increased susceptibility to breakthrough
57 COVID-19.

58 **Conclusion and Relevance:** The implemented vaccination strategy to date has been effective for pwMS
59 on all DMTs other than S1PRM and aCD20. As B-cell immunity seems to be a more important predictor of
60 vaccine effectiveness than T-cell immunity, optimization of humoral immunogenicity and ensuring its
61 durability among pwMS on DMTs are the necessities of an effective COVID-19 vaccination policy.

62 **Key Words:** multiple sclerosis; disease-modifying therapies; COVID-19; vaccination; meta-analysis.

63 **1. Introduction**

64 From the beginning of the coronavirus disease 2019 (COVID-19), global mass vaccination has been the
65 most prominent effort of humanity to end the reign of severe acute respiratory syndrome coronavirus 2
66 (SARS-CoV-2). Ever since, many vaccines have been developed, all with reasonable safety and efficacy
67 profiles (more information available at: <https://covid19.trackvaccines.org/agency/who>).

68 As the effectiveness of COVID-19 vaccination was thought to be altered in people with multiple sclerosis
69 (pwMS) who receive immunomodulatory disease-modifying therapies (DMTs), expert panels issued
70 adjusted vaccination guidelines for pwMS based on previous knowledge of the DMTs' mechanisms of
71 action and preliminary real-world evidence¹⁻⁴. These guidelines mostly concerned people on sphingosine
72 1-phosphate receptor modulators (S1PRM), anti-CD20 therapies (aCD20), and other B-cell depleting
73 therapies (BCDT), as they were thought to blunt COVID-19 vaccines' immunogenicity.

74 Furthermore, administration of booster – in most cases, third – doses of COVID-19 vaccines was
75 recommended after observation of waning humoral immunity⁵ and clinical effectiveness⁶⁻⁸. It was
76 stressed after showing to be effective against the vaccine-escape⁹ Omicron variant of the SARS-CoV-2
77¹⁰⁻¹² – regardless of the priming regimen^{13,14}. Among the pwMS, homologous booster doses were tested
78 as a strategy to immunize the ones who did not seroconvert following their priming regimen.

79 Now, several months after the mass vaccination of pwMS around the globe, the available real-world
80 evidence seems adequate for a practical appraisal of the COVID-19 vaccination policies among pwMS
81 with respect to their DMT. Hence, in this systematic review and meta-analysis study, we aimed to gather
82 and synthesize the available evidence and highlight the gaps in the literature, providing a direction guide
83 for future research, facilitating further policy makings, and enabling evidence-based management of
84 pwMS.

85 We hereby reported and discussed the results of our study (PROSPERO id: CRD42021278107) in
86 accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
87 statement (available from: <http://www.prisma-statement.org>). The detailed methods of our study could be
88 accessed from the online Supplementary Material.

89 **2. Results and Discussion**

90 Overall, 28 studies including 5,025 pwMS and 1,635 healthy controls were synthesized (**Fig. 1, Table 1**).
91 One study¹⁵ was excluded despite containing eligible participants because their data could not be
92 extracted. The studies differed in outcome measurement methods, settings, number of participants, and
93 the administered vaccines. The assessed vaccines used either mRNA (BNT162b2, mRNA-1273),
94 adenoviral vector (AV) (Ad26.COV2.S, ChAdOx1), or inactivated (CoronaVac, BBIBP-CorV) platforms.

95 Other prominent points of heterogeneity were the used assays, the number/types of assessed DMTs, the
96 usage of different comparators, e.g., healthy participants, pwMS on no DMT etc., and the timepoints of
97 obtaining samples from participants.

98 [Fig. 1] [Table 1]

99 The results of individual studies, heterogeneity tests, forest and funnel plots, and the detailed rationale
100 behind each quality assessment – based on NIH tools – is accessible from the online Supplementary
101 Material. The pooled measures are summarized in both **Table 2 and Figure 2**, along with their certainty
102 based on GRADE.

103 [Fig. 2] [Table 2]

104 **2.1. Effect of DMTs on COVID-19 vaccines' immunogenicity**

105 **2.1.1. Interferons (IFN)**

106 Moderate-certainty evidence does not suggest decreased odds of post-vaccination seroconversion in the
107 pwMS on IFNs compared to people unexposed (UX) to DMTs (OR [95%CI]: 0.84 [0.38, 1.83], P=0.66)
108 (Supplementary Figure 1). No seronegative pwMS on IFN were present in four studies¹⁶⁻¹⁹. Quantitative
109 analysis in studies also did not suggest lower concentrations of antibodies among these pwMS post-
110 vaccination. In one study, significantly higher concentrations of anti-Spike (S) receptor binding domain
111 (RBD) IgG were detected among pwMS on IFNs, compared to healthy controls¹⁹. Although the authors
112 suggested that IFN-beta 1a therapy may promote the post-vaccination antibody responses in pwMS, this
113 finding was not observed in other studies.

114 Very-low-certainty evidence from one study²⁰ showed lower extents of interferon-gamma release
115 response to the S antigen in samples from pwMS on IFNs, suggesting blunted T-cell response among
116 these people compared to healthy controls (OR [95%CI]: 0.02 [0.00, 0.28], P<0.01). Both CD4+ and
117 CD8+ T-cell responses were reduced in samples of pwMS on IFN compared to UX people, according to
118 flow cytometric analysis in Tortorella et al. study²⁰.

119 **2.1.2. Glatiramer Acetate (GA)**

120 Moderate-certainty evidence did not suggest decreased odds of post-vaccination seroconversion in the
121 pwMS on GA compared to the UX people (OR [95%CI]: 0.87 [0.31, 2.42], P=0.79) (Supplementary Figure
122 2). Post-vaccination seronegative pwMS on GA were only present in two studies^{21,22} – all being among
123 the ones receiving inactivated vaccination. Quantitative analysis in suggested no difference in post-
124 vaccination antibody concentrations between GA-treated pwMS and the UX people in any study.

125 One study with limited sample size utilizing AIM assays²³ (very low-certainty evidence), suggested
126 decreased odds of positive response neither in CD4+ (OR not measurable) nor CD8+ (OR [95%CI]: 0.62
127 [0.04, 9.00], P=0.72) T-cells. Furthermore, it is worth mentioning that adequate interferon-gamma release

128 responses were present after SARS-CoV-2 *infection* in these people ²⁴, suggesting favorable T-cell
129 responses.

130 **2.1.3. Dimethyl Fumarate (DMF)**

131 Moderate-certainty evidence did not suggest any decrease in odds of post-vaccination seroconversion
132 among pwMS on DMF compared to UX people (OR [95%CI]: 1.98 [0.96, 4.09], P=0.07) (Supplementary
133 Figure 3). Seven studies ^{16,18,19,22,23,25,26} did not contain any seronegative pwMS on DMF following mRNA
134 or inactivated vaccination; Quantitative analysis suggested no difference in post-vaccination antibody
135 concentrations compared to UX people.

136 Similar to GA-treated pwMS, evidence on T-cell responses among these pwMS was limited to one study
137 with a limited sample size ²³ (very-low-certainty evidence), which by utilizing AIM assays, suggested no
138 decrease in odds of positive responses in subsets of CD4+ (OR not measurable) and CD8+ (OR [95%CI]:
139 3.78 [0.18, 78.38], P=0.39) T-cells. Similarly, interferon-gamma release responses were sufficient in
140 DMF-treated pwMS after SARS-CoV-2 *infection*, suggesting adequate T-cell response ²⁴.

141 **2.1.4. Teriflunomide (TERI)**

142 Inadequate number of studies with considerable heterogeneity (very-low-certainty evidence) suggest
143 decreased odds of post-vaccination seroconversion in pwMS on TERI compared to UX people (OR
144 [95%CI]: 0.38 [0.16, 0.90], P=0.03) (Supplementary Figure 4). Due to low number of mRNA vaccine
145 studies with measurable relative effect and therefore, the uncertainty of their pooled measures, the
146 difference between the inactivated and mRNA measures did not reach statistical significance (Chi²=2.91,
147 P=0.09). Nevertheless, considering that none of the TERI-treated pwMS in any of the studies ^{16,18,22,25-28}
148 remained seronegative after mRNA vaccination, the suggested blunt caused by TERI may not be
149 generalizable to the mRNA-vaccinated pwMS. Furthermore, lower antibody concentrations compared to
150 UX people were observed in pwMS on TERI homogenously in all studies regardless of the used vaccine,
151 but reached statistical significance only in one ²⁸. TERI's mechanism of action – which involves inhibition
152 of rapidly-dividing cells, including activated B-cells – may explain this observation.

153 Furthermore, no evidence was found regarding the T-cell responses in these pwMS following vaccination;
154 Assessing the vaccine-induced T-cell responses in TERI-treated pwMS is therefore encouraged.

155 **2.1.5. Sphingosine-1-phosphate receptor modulators (S1PRM)**

156 High-certainty evidence confirms significantly lower odds of post-vaccination seroconversion in pwMS on
157 S1PRM compared with UX people (OR [95%CI]: 0.04 [0.03, 0.06], P<0.00001) (Supplementary Figure 5).
158 All included studies ^{16,17,19-22,25-31} found significantly lower concentrations of antibodies following
159 vaccination in these pwMS compared to UX people. Studies with heterogenous effect measures
160 (moderate-certainty evidence) indicate that with the current vaccination strategy, pwMS on S1PRM are 25
161 times (95%CI: 16.66, 33.33) less likely to show anti-S1, and 8.33 times (95%CI: 3.70, 20) less likely to
162 show anti-S seroconversion following COVID-19 vaccination (Chi²=7.24, P<0.01). Paradoxical to the

163 healthy population, low-certainty evidence – due to limited count of inactivated vaccine studies – suggests
164 that among the pwMS on S1PRM, odds of anti-S1 seroconversion is higher with inactivated vaccines
165 compared to mRNA and AV vaccines ($\text{Chi}^2=11.97$, $P<0.001$). Although theoretically reasonable³², head-
166 to-head mRNA-AV²⁹ and mRNA-inactivated²² immunogenicity comparisons in S1PRM-treated pwMS
167 have suggested the opposite. Hence, the need for more replication of inactivated/mRNA/AV comparisons
168 is clearly sensed for pwMS on S1PRM.

169 Furthermore, interferon-gamma release assays in two studies^{20,26} (low-certainty evidence) suggested
170 decreased odds of positive T-cell response in pwMS on S1PRM (OR [95%CI]: 0.04 [0.02, 0.07],
171 $P<0.00001$) (Supplementary Figure 6). AIM assay in another study²³ (very-low-certainty evidence) did not
172 suggest decreased odds of CD8+ T-cell response in these pwMS (OR [95%CI]: 0.95 [0.08, 10.71],
173 $P=0.97$) but suggested decreased odds of CD4+ T-cell responses (OR [95%CI]: 0.01 [0.00, 0.18],
174 $P=0.001$) compared to UX people.

175 Additionally, among the pwMS on S1PRM who failed to seroconvert following priming vaccination, one
176 study showed that administration of booster doses increased anti-S1 antibody concentrations, but
177 promoted seroconversion only in 2/29 (7%)³³.

178 The trafficking inhibition of lymphocytes, their restriction to lymphatics, and hence, the peripheral
179 lymphopenia seen in pwMS on S1PRM explains the lower T-cell reactivity observed in peripheral blood
180 samples – not to mention S1PRM's documented inhibitive effect on T-cell activation³⁴. The former reason
181 may also explain the blunted humoral responses, as the one-way flow of lymph from peripheral to central
182 areas restricts trafficking of lymphocytes to peripheral areas, inhibiting proper exposure of lymph-trapped
183 lymphocytes to immunizing materials of the vaccines which are administered peripherally/locally. As
184 systemic SARS-CoV-2 infection mounts adequate immunization among pwMS on S1PRM^{32,35}, it can be
185 hypothesized that immunogenicity in these people is subject to wider (e.g., systemic instead of
186 local/peripheral) exposure to immunogens. When the lymphocytes' ability to reach the immunogens is
187 inhibited, the immunogens should reach the lymphocytes themselves or immunization will not develop.

188 **2.1.6. Natalizumab (NTZ)**

189 Compared to UX people, low-certainty evidence did not confirm lower odds of anti-S1 seroconversion
190 among pwMS on NTZ following vaccination (OR [95%CI]: 0.53 [0.24, 1.18]) (Supplementary Figure 7). All
191 pwMS on NTZ in seven studies – including the only two studies using anti-S assays with extractable data
192^{23,36} – seroconverted following vaccination^{16,17,23,25,26,28,36}. Although relative effect was measurable in only
193 two of them which contained seronegative UX people^{26,28}. Unlike all the other studies, pwMS on NTZ in
194 one study²⁸ showed significantly lower post-vaccination antibodies compared to UX people. Interferon-
195 gamma release¹⁷ and AIM²³ assays (very low-certainty evidence) did not suggest blunted post-
196 vaccination T-cell responses in pwMS on NTZ compared to UX people.

197 NTZ, an anti- α 4-integrin monoclonal antibody, implements its effect by inhibiting lymphocyte
198 extravasation; however, unlike S1PRM, its lymphocyte trafficking inhibition does not trap the lymphocytes
199 in the lymphatic system – i.e., it does not cause peripheral lymphopenia. Although their trafficking abilities
200 are inhibited, the preserved presence of lymphocytes in blood flow – which, unlike the lymph flow, can be
201 from central to peripheral areas as well – may be the reason NTZ does not blunt vaccination-induced
202 immunization as much as S1PRM.

203 **2.1.7. Cladribine (CLAD)**

204 Pooled low-certainty evidence (Supplementary Figure 8) confirms no difference in odds of anti-S1
205 seroconversion among pwMS on CLAD compared to UX people (OR [95%CI]: 0.41 [0.15, 1.11], P=0.08).
206 No evidence was found regarding anti-S seroconversion. In five studies^{16,19,20,22,25}, all CLAD-treated
207 pwMS seroconverted following vaccination similar to the UX people, preventing relative effect
208 measurement. Quantitative analysis in no studies suggested lower concentrations of post-vaccination
209 antibodies among them. Assessment of vaccination-induced T-cell response was limited to one study²⁰
210 (very-low-certainty evidence); it showed lower odds of positive S-induced interferon-gamma release
211 responses in samples from pwMS on CLAD compared to UX people (OR [95%CI]: 0.01 [0.00, 0.04],
212 P<0.00001).

213 Compared to its effect on the T-cell lineage, CLAD's effect on the B-cells is more extensive but less
214 durable³⁷⁻⁴⁰. As interpreted, this has been translated into observation of proper humoral despite blunted
215 cellular immunization following COVID-19 vaccination among pwMS on CLAD. Furthermore, the time
216 since the last CLAD dose theoretically affects humoral responses; This was suggested especially by
217 Achiron et al. study²⁶ but did not reach statistical significance, and was not confirmed by other studies
218^{25,28,41}; It seems the implemented guidelines¹⁻⁴ have suggested an adequate amount of post-CLAD
219 vaccination delay to prevent blunted humoral responses, and therefore, made the probable effect
220 unmeasurable. Additionally, although CLAD depletes the memory B-cells⁴², a preliminary study
221 suggested its subsequent doses will not alter pre-existing humoral memory⁴³; Still, there is limited
222 evidence that the longevity of COVID-19 vaccine-induced humoral responses is lower in pwMS on CLAD
223²⁶. Replicative studies measuring the immunity waning speed in these pwMS after COVID-19 vaccination
224 are, therefore, required to determine whether they require personalized booster schedules.

225 **2.1.8. Alemtuzumab (ALEM)**

226 Pooled very-low-certainty evidence (Supplementary Figure 9) suggests lower odds of anti-S1
227 seroconversion among pwMS on ALEM compared to UX people (OR [95%CI]: 0.32 [0.10, 0.96], P=0.04).
228 One study assessed anti-S seroconversion, but its data could not be extracted³⁰. PwMS on ALEM in
229 three studies^{16,25,28} showed 100% seroconversion rates similar to the UX people in two of them^{16,25}, and
230 none of the studies suggested lower concentrations of post-vaccination antibodies among them – not
231 even the study that indicated lower odds of seroconversion²⁶. Vaccination-induced T-cell responses were

232 not assessed in any of the included studies, still, ALEM's durable effect of T-cell lineage⁴⁴ suggests that
233 they are blunted .

234 ALEM, an anti-CD52 monoclonal antibody, is known to significantly deplete B- and T-cells shortly after
235 administration. ALEM's short-term effect on B- and T-cell dynamics is relatively similar to CLAD^{40,44}.
236 Hence, although the time from the last ALEM infusion affects seroconversion²⁶, this effect is currently not
237 measurable as the implemented guidelines¹⁻⁴ seem to have suggested an adequate amount of delay.
238 Similar to other BCDT, further studies measuring comparative immunity waning speeds in pwMS on
239 ALEM are needed to determine whether they require more frequent boosters.

240 **2.1.9. Anti-CD20 therapies (aCD20)**

241 High-certainty evidence confirms lower odds of seroconversion following COVID-19 vaccination among
242 pwMS on aCD20 compared to UX people (OR [95%CI]: 0.05 [0.04, 0.06], P<0.00001) (Supplementary
243 Figure 10). Studies with heterogenous effect measures (moderate-certainty evidence) indicate that with
244 the currently-implemented strategies, pwMS on aCD20 are 20 times (95%CI: 16.66, 25) less likely to
245 seroconvert for anti-S1, and 12.5 times (95%CI: 7.69, 20) less likely to seroconvert for anti-S antibodies
246 ($\text{Chi}^2=2.76$, P=0.10) following COVID-19 vaccination. Quantitative analyses in all included studies
247 confirmed this observation. Furthermore, evidence indicates with high certainty that every 10-week delay
248 in subsequent aCD20 infusion is associated with a 1.94-time (95%CI: 1.57, 2.41, P<0.00001) increase in
249 seroconversion odds of pwMS on aCD20 (Supplementary Figure n).

250 Regarding the T-cell responses, compared to UX people, moderate-certainty evidence does not suggest
251 different odds of positive post-vaccination T-cell interferon-gamma release responses (OR [95%CI]: 1.12
252 [0.62, 2.05], P=0.70) (Supplementary Figure 12), CD8+ (OR [95%CI]: 2.54 [0.89, 7.27], P=0.08)
253 (Supplementary Figure 13), and CD4+ (OR [95%CI]: 1.13 [0.17, 7.61], P=0.90) T-cell AIM responses.
254 Quantitative analyses in most studies^{17,20,23,29,45-48} were in line with the dichotomized evidence. Multiplex
255 polymerase chain reaction assay in one study⁴⁹ indicated positive adaptive T-cell responses among 100%
256 of seronegative pwMS on aCD20 following vaccination.

257 Furthermore, the preliminary evidence indicates significant decline in seropositivity rates of pwMS on
258 aCD20 six months after their second dose^{50,51}. Homologous mRNA boosters in pwMS on aCD20
259 promoted T-cell responses⁵², while humoral responses were still heavily dependent on the serostatus
260 following the priming regimen, and B-cell dynamics at the time of booster administration^{33,51-53}. In other
261 words, the booster doses did not promote humoral immunization in pwMS on aCD20 who did not
262 seroconvert following priming vaccination, unless their B-cells were reconstituted. Studies among people
263 on aCD20 with diseases other than MS^{54,55} support the same conclusion.

264 Similar to pwMS on other DMTs, the COVID-19 vaccines' immunogenicity among pwMS on aCD20 could
265 be considered a translation of the previously-determined B- and T-cell dynamics in them^{40,56}, based on
266 which the current guidelines recommended a 12-to-36-week window between aCD20 infusion and

267 COVID-19 vaccination ¹⁻⁴. However, the presented evidence suggests that the mentioned interval,
268 although increases the odds, will not be adequate to reverse the humoral blunts in pwMS on aCD20 (Fig.
269 3). The alterations in the dynamics of B-cells in people receiving aCD20 last for years according to the
270 unpublished results from the NCT00676715 phase-II extension trial ⁵⁷, suggesting durable, long-lasting
271 benefits of aCD20 without subsequent dosing ⁵⁸. However, this durable effect of aCD20 has shown to be
272 able to alter vaccine immunogenicity for as long as three years, as observed in people with hematological
273 malignancies ⁵⁹. Hence, prior B-cell profiling and post-vaccination serological screening may be the
274 necessities of an effective personalized vaccination strategy in pwMS who received aCD20 at any time
275 point within three years.

276 [Fig. 3]

277 **2.2. Vaccine types**

278 Based on phase-III data, the efficacy profiles of different available COVID-19 vaccine types (i.e., mRNA,
279 AV, inactivated, and protein-based) seems to correlate to their anti-S/S1 humoral immunogenicity – both
280 in healthy people ^{60,61} and pwMS ⁶². Head-to-head comparisons of the available COVID-19 vaccines'
281 humoral immunogenicity among pwMS reveals the superiority of mRNA-1237 over BNT162b2 (both
282 mRNA-based) ^{20,25,63} – probably due to higher concentrations of active material, BNT162b2 and mRNA-
283 1237 (mRNA) over ChAdOx1 and Ad26.COVS2 (AV) ^{17,23,29,49} and BNT162b2 (mRNA) over CoronaVac
284 (inactivated) ²² – although humoral immunization did not differ significantly in pwMS on aCD20 receiving
285 BNT162b2 and CoronaVac in Ozakbas et al. ²² study. The choice of a specific vaccine type among pwMS
286 is encouraged and should be based on an individualized risk/benefit assessment with careful
287 consideration of their COVID-19 risk factor profile ^{64,65}, their DMT, and the availability/cost-effectiveness
288 of the vaccine ^{66,67}.

289 **2.3. Moving into the clinic**

290 While the serum anti-S/S1 assays are deemed predictive of its neutralizing activity ^{68,69}, and the serum
291 neutralizing activity predictive of the clinical protection against symptomatic SARS-CoV-2 infection ⁷⁰,
292 pwMS with adequate humoral responses – mostly on DMTs other than aCD20 and S1PRM – would
293 theoretically show adequate protection against SARS-CoV-2. However, in the absence of humoral
294 immunization, it is doubted if the T-cells could provide adequate clinical protection among pwMS on
295 aCD20 and S1PRM. The current real-world evidence confirms the predictive effect of seroconversion on
296 post-vaccination COVID-19 incidence and severity ⁶², and indicates rising comparative incidence and
297 severity of COVID-19 among pwMS on S1PRM and aCD20 following vaccination of pwMS ^{62,71-73}. The
298 less-extensive humoral blunts in pwMS on TERI – and possibly ALEM – do not seem to have had any
299 significant effect on vaccine effectiveness. Regarding the protective effect of T-cell responses, currently,
300 the only clue lies within the Etemadifar et al. ⁷² study – although not confirmed by a larger study ⁷³; it
301 showed that among the vaccinated pwMS, the ones on aCD20 experienced lower incidence and severity

302 of COVID-19 in comparison with those on fingolimod. The former are known to be prone to worse COVID-
303 19 outcomes⁶⁴ but show robust post-vaccination T-cell responses, while the latter do not develop proper
304 T-cell immunization following vaccination. Still, the practical protective effect of T-cell responses in the
305 absence of antibodies could neither be confirmed nor measured until further real-world evidence
306 becomes available.

307 **3. Conclusion**

308 The present analysis highlight and corroborate the relevance for an optimal treatment strategy in pwMS
309 before COVID-19 vaccination. It was demonstrated that the current vaccination strategy has failed to
310 promote adequate humoral immunity in aCD20- and S1PRM-treated pwMS, which is being translated into
311 low clinical effectiveness of COVID-19 vaccines among them – despite adequate T-cell responses in the
312 ones on aCD20. Their susceptibility to worse COVID-19 outcomes, and the dependency of COVID-19
313 vaccines' humoral immunogenicity to the B-cell dynamics at the time of administration – and therefore,
314 the timing of aCD20 infusion – stress the importance of personalizing vaccination strategies for pwMS on
315 aCD20 with respect to their B-cell profiles and aCD20 infusion timings. Theoretically and based on limited
316 evidence, mode of action and administration method may be important factors to consider also when
317 vaccinating S1PR modulator-treated pwMS, while more evidence is needed to support this claim. Milder
318 humoral and considerable T-cell response blunts – also depending on dosage timings, and higher
319 immunity waning speeds may be present in pwMS on CLAD and ALEM, which subject to confirmation by
320 further evidence, stresses the importance of earlier booster administrations among them. TERI may also
321 cause a humoral immunogenicity blunt, however, being less extensive and clinically-irrelevant based on
322 current evidence; PwMS on TERI may not require countering policies other than being provided with
323 reliable information about the importance of booster doses. Evidence to date does not indicate any
324 significant effect of IFN, GA, DMF, and NTZ on COVID-19 vaccines' immunogenicity and effectiveness.

325 Additionally, as heterologous boosters among healthy people showed to be more immunogenic and
326 effective⁷⁴, further replication among pwMS with heterologous regimens is encouraged, especially among
327 the ones primed with inactivated vaccines – as samples from inactivated-vaccinated people show less
328 neutralizing activity against the Omicron variant⁷⁵, and the heterologous boosters with superiority of
329 mRNA^{13,14,76-78} over AV⁷⁹ have shown to be more immunogenic than homologous boosters in healthy
330 people receiving inactivated priming regimens.

331 **4. Acknowledgements**

332 We would like to thank Prof. Mohammad Reza Maracy for his valuable methodological consultations.

333 ***5. Conflict of Interest and Funding***

334 The authors declare no conflict of interest. This study did not receive any funding.

335

6. References

- 336 1. Timing MS Medications with COVID-19 Vaccines. National MS Society.
337 Accessed 19 November 2021. [https://www.nationalmssociety.org/coronavirus-covid-19-](https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines)
338 [information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-](https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines)
339 [Medications-with-COVID-19-Vaccines](https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines)
- 340 2. Yamout BI, Zakaria M, Inshasi J, et al. MENACTRIMS practice guideline for
341 COVID-19 vaccination in patients with multiple sclerosis. *Multiple Sclerosis and Related*
342 *Disorders*. 2021;56:103225.
- 343 3. MS, DMTs and COVID-19 vaccines consensus statement. Multiple Sclerosis
344 Society. Accessed 13 January, 2022. [https://www.mssociety.org.uk/what-we-](https://www.mssociety.org.uk/what-we-do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines)
345 [do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines](https://www.mssociety.org.uk/what-we-do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines)
- 346 4. Wolf A, Alvarez E. COVID-19 Vaccination in Patients With Multiple Sclerosis on
347 Disease-Modifying Therapy. *Neurology: Clinical Practice*. 2021;
- 348 5. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to
349 BNT162b2 Covid-19 vaccine over 6 months. *New England Journal of Medicine*.
350 2021;385(24):e84.
- 351 6. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2
352 vaccine in Israel. *New England Journal of Medicine*. 2021;385(24):e85.
- 353 7. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 Vaccine Effectiveness in
354 New York State. *N Engl J Med*. Jan 13 2022;386(2):116-127.
355 doi:10.1056/NEJMoa2116063
- 356 8. Lin DY, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-
357 Month Period in North Carolina. *N Engl J Med*. Jan 12
358 2022;doi:10.1056/NEJMoa2117128
- 359 9. Edara VV, Manning KE, Ellis M, et al. mRNA-1273 and BNT162b2 mRNA
360 vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
361 *bioRxiv*. Dec 22 2021;doi:10.1101/2021.12.20.473557
- 362 10. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of
363 mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2
364 Omicron and Delta Variants. *Jama*. Jan 21 2022;doi:10.1001/jama.2022.0470
- 365 11. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits
366 potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nat Med*.
367 Jan 19 2022:1-4. doi:10.1038/s41591-021-01676-0
- 368 12. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19
369 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
370 *Cell*. Jan 6 2022;doi:10.1016/j.cell.2021.12.033
- 371 13. Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the
372 SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus
373 BNT162b2 booster vaccination. *Nat Med*. Jan 20 2022;doi:10.1038/s41591-022-01705-
374 6
- 375 14. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the
376 SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or
377 BNT162b2 vaccination. *Nat Med*. Jan 20 2022;doi:10.1038/s41591-022-01704-7

- 378 15. Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J. Impact of
379 disease-modifying treatments on humoral response after COVID-19 vaccination: a
380 mirror of the response after SARS-CoV-2 infection. *Revue Neurologique*. 2021;
381 16. Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA
382 COVID-19 vaccines in people with multiple sclerosis treated with different disease-
383 modifying therapies. *Neurotherapeutics*. 2021:1-9.
384 17. Gadani SP, Reyes-Mantilla M, Jank L, et al. Discordant humoral and T cell
385 immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-
386 CD20 therapy. *EBioMedicine*. 2021;73:103636.
387 18. Giossi R, Consonni A, Clerici VT, et al. Anti-Spike IgG in multiple sclerosis
388 patients after BNT162b2 vaccine: An exploratory case-control study in Italy. *Multiple*
389 *Sclerosis and Related Disorders*. 2021:103415.
390 19. Maniscalco GT, Manzo V, Ferrara AL, et al. Interferon Beta-1a treatment
391 promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. *Multiple*
392 *sclerosis and related disorders*. 2022;58:103455.
393 20. Tortorella C, Aiello A, Gasperini C, et al. Humoral-and T-Cell – Specific Immune
394 Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different
395 Disease-Modifying Therapies. *Neurology*. 2021;
396 21. Etemadifar M, Sedaghat N, Nouri H, et al. SARS-CoV-2 serology among people
397 with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm)
398 inactivated virus vaccination: Same story, different vaccine. *Multiple Sclerosis and*
399 *Related Disorders*. 2022;57:103417.
400 22. Ozakbas S, Baba C, Dogan Y, Cevik S, Ozcelik S, Kaya E. Comparison of
401 SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in
402 multiple sclerosis patients treated with disease-modifying therapies. *Multiple sclerosis*
403 *and related disorders*. 2022:103486.
404 23. Sabatino Jr JJ, Mittl K, Rowles W, et al. Impact of multiple sclerosis disease-
405 modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.
406 *medRxiv*. 2021;
407 24. Kister I, Patskovsky Y, Curtin R, et al. Cellular and humoral immunity to SARS-
408 CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-
409 modifying therapies: a multi-ethnic observational study. *medRxiv*. 2022;
410 25. Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA
411 vaccination in MS patients treated with disease modifying therapies. *EBioMedicine*.
412 2021;72:103581.
413 26. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response in
414 multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6
415 months cross-sectional study. *Journal of Neuroimmunology*. 2021;361:577746.
416 27. Disanto G, Sacco R, Bernasconi E, et al. Association of disease-modifying
417 treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2
418 vaccines in patients with multiple sclerosis. *JAMA neurology*. 2021;78(12):1529-1531.
419 28. Pitzalis M, Idda ML, Lodde V, et al. Effect of different disease-modifying
420 therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis
421 patients. *Frontiers in immunology*. 2021:5233.
422 29. Tallantyre EC, Vickaryous N, Anderson V, et al. COVID - 19 Vaccine Response
423 in People with Multiple Sclerosis. *Annals of neurology*. 2022;91(1):89-100.

- 424 30. König M, Lorentzen ÅR, Torgauten HM, et al. Humoral immunity to SARS-CoV-2
425 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab
426 infusion and first experience from sporadic revaccinations. *Journal of Neurology,*
427 *Neurosurgery & Psychiatry*. 2021;
- 428 31. Türkoğlu R, Baliç N, Kızılay T, et al. 7Fingolimod impairs inactivated vaccine
429 (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with
430 multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2022:103524.
- 431 32. Rommer PS, Bsteh G, Berger T, Zettl UK. SARS-CoV-2 antibodies in multiple
432 sclerosis patients depending on the vaccine mode of action? *Multiple Sclerosis Journal*.
433 2022;28(1):165-167.
- 434 33. König M, Torgauten HM, Øverås MH, et al. Efficacy and safety of a third SARS-
435 CoV-2 vaccination in multiple sclerosis vaccine non-responders. *medRxiv*.
436 2021:2021.10.15.21264977. doi:10.1101/2021.10.15.21264977
- 437 34. Baer A, Colon-Moran W, Bhattarai N. Characterization of the effects of
438 immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling
439 pathways. *Scientific Reports*. 2018/07/19 2018;8(1):10910. doi:10.1038/s41598-018-
440 29355-0
- 441 35. Sormani MP, Schiavetti I, Landi D, et al. SARS-CoV-2 serology after COVID-19
442 in multiple sclerosis: An international cohort study. *Multiple Sclerosis Journal*.
443 2021:13524585211035318.
- 444 36. Capuano R, Donnarumma G, Biseco A, et al. Humoral response to SARS-CoV-
445 2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab.
446 *Therapeutic Advances in Neurological Disorders*. 2021;14:17562864211038111.
- 447 37. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine
448 for relapsing multiple sclerosis. *New England Journal of Medicine*. 2010;362(5):416-426.
- 449 38. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory
450 and naive human B cell subsets and implication in multiple sclerosis. *The Journal of*
451 *Immunology*. 2007;178(10):6092-6099.
- 452 39. Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte
453 reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
454 *Multiple sclerosis and related disorders*. 2019;29:168-174.
- 455 40. Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. CD19
456 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for
457 SARS-CoV-2 vaccinations in multiple sclerosis. *Multiple Sclerosis and Related*
458 *Disorders*. 2022;57:103448.
- 459 41. Grothe C, Steffen F, Bittner S. Humoral immune response and lymphocyte levels
460 after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients
461 treated with cladribine tablets. *Journal of Central Nervous System Disease*.
462 2021;13:11795735211060118.
- 463 42. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are
464 major targets for effective immunotherapy in relapsing multiple sclerosis. *EBioMedicine*.
465 2017;16:41-50.
- 466 43. Moser T, O'Sullivan C, Puttinger C, et al. Pre-Existing Humoral Immunological
467 Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
468 *Biomedicines*. 2021;9(11):1584.

- 469 44. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis:
470 mechanism of action and beyond. *International journal of molecular sciences*.
471 2015;16(7):16414-16439.
- 472 45. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune
473 responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
474 on anti-CD20 therapy. *Nature medicine*. 2021;27(11):1990-2001.
- 475 46. Madelon N, Lauper K, Breville G, et al. Robust T cell responses in anti-CD20
476 treated patients following COVID-19 vaccination: a prospective cohort study. *Clinical*
477 *Infectious Diseases*. 2021;
- 478 47. Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2
479 vaccination in patients with multiple sclerosis treated with ocrelizumab. *JAMA neurology*.
480 2021;78(12):1510-1514.
- 481 48. Pomsch M, Fisenkci N, Horn PA, Kraemer M, Lindemann M. Evidence of
482 extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-
483 treated patients with multiple sclerosis. *Neurological Research and Practice*.
484 2021;3(1):1-6.
- 485 49. Katz J, Bouley A, Jungquist R, Douglas E, O'Shea I, Lathi E. Humoral and T-cell
486 responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with
487 ocrelizumab. *Multiple Sclerosis and Related Disorders*. 2021:103382.
- 488 50. Bajwa HM, Novak F, Nilsson AC, et al. Persistently reduced humoral and cellular
489 immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated
490 multiple sclerosis patients. *medRxiv*. 2022;
- 491 51. Brill L, Raposo C, Rechtman A, et al. SARS-CoV-2 third vaccine immune
492 response in MS patients treated with ocrelizumab. *medRxiv*. 2022;
- 493 52. Madelon N, Heikkilä N, Sabater Royo I, et al. Omicron-specific cytotoxic T-cell
494 responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-
495 treated multiple sclerosis patients. *medRxiv*. 2021:2021.12.20.21268128.
496 doi:10.1101/2021.12.20.21268128
- 497 53. Achtnichts L, Jakopp B, Oberle M, et al. Humoral Immune Response after the
498 Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis.
499 *Vaccines*. 2021;9(12):1470.
- 500 54. Felten R, Gallais F, Schleiss C, et al. Cellular and humoral immunity after the
501 third dose of SARS-CoV-2 vaccine in patients treated with rituximab. *Lancet Rheumatol*.
502 Jan 2022;4(1):e13-e16. doi:10.1016/s2665-9913(21)00351-9
- 503 55. Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous
504 booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody
505 seroconversion after primary mRNA vaccination: a randomised controlled trial. *Ann*
506 *Rheum Dis*. Jan 13 2022;doi:10.1136/annrheumdis-2021-221558
- 507 56. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple
508 sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *The Lancet*.
509 2011;378(9805):1779-1787.
- 510 57. Hauser S, Li D, Calabresi P, et al. Week 144 results of a phase II, randomized,
511 multicenter trial assessing the safety and efficacy of ocrelizumab in patients with
512 relapsing – remitting multiple sclerosis (RRMS)(S31. 004). AAN Enterprises; 2013.

- 513 58. Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II
514 extension trial suggests the potential to improve the risk: Benefit balance in multiple
515 sclerosis. *Multiple Sclerosis and Related Disorders*. 2020;44:102279.
- 516 59. Funakoshi Y, Yakushijin K, Ohji G, et al. Increase in Antibody Titers Following
517 Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of
518 Anti-CD20 Antibody. *Blood*. 2021;138:534.
- 519 60. Fan Y-J, Chan K-H, Hung IF-N. Safety and Efficacy of COVID-19 Vaccines: A
520 Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. *Vaccines*.
521 2021;9(9):989.
- 522 61. Cheng H, Peng Z, Luo W, et al. Efficacy and Safety of COVID-19 Vaccines in
523 Phase III Trials: A Meta-Analysis. *Vaccines*. 2021;9(6):582.
- 524 62. Sormani MP, Schiavetti I, Inglese M, et al. Breakthrough SARS-CoV-2 infections
525 after COVID-19 mRNA vaccination in MS patients on disease modifying therapies.
526 *medRxiv*. 2021;
- 527 63. Ali A, Dwyer D, Wu Q, et al. Characterization of humoral response to COVID
528 mRNA vaccines in multiple sclerosis patients on disease modifying therapies. *Vaccine*.
529 2021;39(41):6111-6116.
- 530 64. Etemadifar M, Nouri H, Maracy MR, et al. Risk factors of severe COVID-19 in
531 people with multiple sclerosis: A systematic review and meta-analysis. *Revue*
532 *neurologique*. 2021;
- 533 65. Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 severity in multiple
534 sclerosis: putting data into context. *Neurology-Neuroimmunology Neuroinflammation*.
535 2022;9(1)
- 536 66. López F, Català M, Prats C, et al. A Cost-Benefit Analysis of COVID-19
537 Vaccination in Catalonia. *Vaccines (Basel)*. Dec 31
538 2021;10(1)doi:10.3390/vaccines10010059
- 539 67. Vaezi A, Meysamie A. COVID-19 Vaccines Cost-Effectiveness Analysis: A
540 Scenario for Iran. *Vaccines (Basel)*. Dec 29 2021;10(1)doi:10.3390/vaccines10010037
- 541 68. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation
542 of six high-throughput SARS-CoV-2 IgG antibody assays. *Journal of Clinical Virology*.
543 2020/08/01/ 2020;129:104480. doi:<https://doi.org/10.1016/j.jcv.2020.104480>
- 544 69. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2
545 serological assays in a high-prevalence setting. *European Journal of Clinical*
546 *Microbiology & Infectious Diseases*. 2021/05/01 2021;40(5):1063-1071.
547 doi:10.1007/s10096-021-04169-7
- 548 70. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
549 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*
550 *Medicine*. 2021/07/01 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
- 551 71. Garjani A, Patel S, Bharkhada D, et al. Impact of mass vaccination on SARS-
552 CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-
553 modifying therapies in England. *Multiple Sclerosis and Related Disorders*.
554 2022;57:103458.
- 555 72. Etemadifar M, Abhari AP, Nouri H, Eighani N, Salari M, Sedaghat N. Effect of
556 Disease-Modifying Therapies on Clinical Efficacy of COVID-19 Inactivated Vaccination
557 among People with Multiple Sclerosis. *Available at SSRN 3998537*. 2022;

- 558 73. Schiavetti I, Cordioli C, Stromillo ML, et al. Breakthrough SARS-CoV-2 infections
559 in MS patients on disease modifying therapies. *medRxiv*. 2022:2022.01.22.22269630.
560 doi:10.1101/2022.01.22.22269630
- 561 74. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous
562 versus homologous prime-boost schedules with an adenoviral vectored and mRNA
563 COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet*.
564 Sep 4 2021;398(10303):856-869. doi:10.1016/s0140-6736(21)01694-9
- 565 75. Peiris M, Cheng S, Mok CKP, et al. Neutralizing antibody titres to SARS-CoV-2
566 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted
567 with mRNA BNT162b2 or inactivated CoronaVac vaccines. *Res Sq*. Jan 5
568 2022;doi:10.21203/rs.3.rs-1207071/v1
- 569 76. Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and Immunogenicity
570 of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines
571 in Fully Immunized Healthy Adults with Inactivated Vaccine. *Vaccines*. 2022;10(1):86.
- 572 77. Wang X, Zhao X, Song J, et al. Homologous or Heterologous Booster of
573 Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing
574 Antibodies. *Emerg Microbes Infect*. Jan 15 2022:1-18.
575 doi:10.1080/22221751.2022.2030200
- 576 78. Zhang R, Liu D, Leung KY, et al. Immunogenicity of a Heterologous Prime-Boost
577 COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with
578 Homologous Vaccination Strategy against SARS-CoV-2 Variants. *Vaccines (Basel)*. Jan
579 3 2022;10(1)doi:10.3390/vaccines10010072
- 580 79. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and
581 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored
582 COVID-19 vaccines in healthy adults. *medRxiv*. 2021:2021.11.04.21265908.
583 doi:10.1101/2021.11.04.21265908
- 584 80. Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with
585 multiple sclerosis: what we have learnt by February 2021. *Multiple Sclerosis Journal*.
586 2021:135245852110034.
- 587 81. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to
588 COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy
589 disease-modifying therapies. *Therapeutic advances in neurological disorders*.
590 2021;14:17562864211012835.
- 591 82. Gallo A, Capuano R, Donnarumma G, et al. Preliminary evidence of blunted
592 humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated
593 with ocrelizumab. *Neurological Sciences*. 2021;42(9):3523-3526.
- 594 83. van Kempen Z, Wieske L, Stalman E, et al. Longitudinal humoral response after
595 SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
596 *Multiple Sclerosis and Related Disorders*. 2022;57:103416.
- 597 84. Guerrieri S, Lazzarin S, Zanetta C, Nozzolillo A, Filippi M, Moiola L. Serological
598 response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with
599 fingolimod or ocrelizumab: an initial real-life experience. *J Neurol*. 2021;1:1-5.
- 600 85. Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following
601 SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
602 *Multiple Sclerosis and Related Disorders*. 2021;56:103251.

603

604

Tables

605 *Table 1; Characteristics of included studies.*

Study (Location)	Sample size (pwMS, HC)	Vaccine (platform)	B-cell assay (method, manufacturer)	T-cell assay (method, manufacturer)	Study quality*
Achiron et al. (Israel) ^{26,80,81}	503 (414, 89)	BNT162b2 (mRNA)	Serum anti-S1 IgG (ELISA, EUROIMMUN) PBMC S-induced IgG-secreting B-cells (FluoroSpot, Mabtech)	PBMC S-induced IFN-g-, IL-2-positive T-cells (FluoroSpot, Mabtech)	Good
Ali et al. (USA) ⁶³	53 (46**, 7)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum Anti-RBD IgG (CLIA, Siemens)	NA	Fair
Apostolidis et al. (USA) ⁴⁵	30 (20, 10)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum anti-S IgG (ELISA, NA) Serum anti-RBD IgG (ELISA, NA) PBMC S-induced IgG-secreting B-cells (Cell Probe, NA)	PBMC S-induced activation marker-positive T-cells (AIM, NA)	Fair
Bigaut et al. (France) ¹⁵	28 (28, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum anti-RBD IgG (CMIA, Abbot; ECLIA, Roche)	NA	Fair
Brill et al. (Israel) ⁴⁷	112 (72, 40)	BNT162b2 (mRNA)	Serum anti-S IgG (CLIA, DiaSorin) Serum anti-RBD IgG (CMIA, Abbot)	PBMC S/N-induced IFN-g-positive T-cells (ELISpot, Oxford Immunotec)	Fair
Capone et al. (Italy) ¹⁶	140 (140, 0)	BNT162b2 (mRNA)	Serum anti-RBD IgG (CMIA, Abbot)	NA	Good
Capuano et al. (Italy) ³⁶	57 (26, 31)	BNT162b2 (mRNA)	Serum anti-S IgG (CLIA, DiaSorin)	NA	Good
Disanto et al. (Switzerland) ²⁷	116 (116, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum anti-RBD IgG (CMIA, Abbot)	NA	Good
Etemadifar et al. (Iran) ²¹	358 (144, 214)	BBIBP-CorV (Inactivated)	Serum anti-S IgG (ELISA, Pish tazteb)	NA	Good
Gadani et al. (USA) ¹⁷	101 (101, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA) Ad26.COVS.S (AV)	Serum anti-S1 IgG (ELISA, EUROIMMUN)	PBMC S-induced IFN-g-positive T-cells (FluoroSpot, Mabtech)	Fair
Gallo et al. (Italy) ⁸²	59 (4, 55)	BNT162b2 (mRNA)	Serum anti-S IgG (CLIA, DiaSorin)	NA	Fair
Giossi et al. (Italy) ¹⁸	312 (39, 273)	BNT162b2 (mRNA)	Serum anti-RBD IgG (CMIA, Abbot)	NA	Fair
Katz et al. (USA) ⁴⁹	48 (48, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA) Ad26.COVS.S (AV)	Serum anti-RBD IgG (ECLIA, Roche)	Rearranged TCR gene sequences (M-PCR, Adaptive Biotechnologies)	Fair
Koening et al. (Norway) ³⁰	1155 (528, 627)	BNT162b2 (mRNA) mRNA-1273 (mRNA) ChAdOx1 (AV)	PBMC S-induced IgG-secreting B-cells (BBFCA, NA) PBMC RBD-induced IgG-secreting B-cells (BBFCA, NA)	NA	Fair
Madelon et al. (Switzerland) ⁴⁶	48 (26, 22)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum anti-RBD IgG (ECLIA, Roche)	PBMC S-induced activation marker-positive T-cells (AIM, NA)	Fair
Maniscalco et al. (Italy) ¹⁹	149 (125, 24)	BNT162b2 (mRNA)	Serum anti-RBD IgG (ECLIA, Roche)	NA	Good
Ozakbas et al.	591 (547, 44)	BNT162b2 (mRNA)	Serum anti-RBD IgG (CMIA)	NA	Good

(Turkey) ²²		CoronaVac (Inactivated)	Abbot)		
Pitzalis et al. (Italy) ²⁸	975 (912, 63)	BNT162b2 (mRNA)	Serum anti-RBD IgG (ECLIA, Roche)	NA	Fair
Pompsch et al. (Germany) ⁴⁸	30 (10, 20)	BNT162b2 (mRNA)	Serum anti-S1 IgG (ELISA, EUROIMMUN)	S/N/M-induced IFN-g-positive T-cells (ELISpot, Miltenyi Biotec)	Fair
Sabatino et al. (USA) ²³	80 (67, 13)	BNT162b2 (mRNA) mRNA-1273 (mRNA) Ad26.COVS.S (AV)	PBMC S-induced IgG-secreting B-cells (BBFCA, NA) PBMC RBD-induced IgG-secreting B-cells (BBFCA, NA)	PBMC S-induced activated T-cells (AIM; ICS; pMHC, NA)	Fair
Sormani et al. (Italy) ^{25,62}	780 (780, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum anti-RBD IgG (ECLIA, Roche)	NA	Good
Tallantyre et al. (UK) ²⁹	473 (473, 0)	BNT162b2 (mRNA) ChAdOx1 (AV) Ad26.COVS.S (AV)	Serum anti-RBD IgG (ELISA, Kantaro Biosciences; GloBody, NA)	PBMC S/N/M-induced IFN-g-positive T-cells (ELISpot, ImmunoServ Ltd.)	Fair
Tortorella et al. (Italy) ²⁰	186 (108, 78)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Serum anti-RBD IgG (NR) Neutralizing antibodies (MNA, NA)	Whole blood S-induced IFN-g (ELISA, ProteinSimple)	Fair
Turkoglu et al. (Turkey) ³¹	59 (34, 25)	CoronaVac (Inactivated)	Serum anti-S1 IgG (ELISA, EUROIMMUN)	NA	Fair
Van Kempen et al. (Netherlands) ⁸³	87 (87, 0)	mRNA-1273 (mRNA)	Serum anti-RBD IgG (ELISA, NR)	NA	Fair
Studies with no comparators					
Guerrieri et al. (Italy) ⁸⁴	32 (32, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA)	Various assays	NA	NA
Novak et al. (Denmark, USA) ⁸⁵	60 (60, 0)	mRNA vaccines	Serum anti-RBD IgG (CMIA, Abbot)	NA	NA
Grothe et al. (Germany) ⁴¹	38 (38, 0)	BNT162b2 (mRNA) mRNA-1273 (mRNA) ChAdOx1 (AV)	Serum anti-S IgG (CLIA, DiaSorin)	NA	NA

*Assessed with National Institutes of Health quality assessment tools (The rationale of judgements are presented in an online supplementary file; The used criteria are available at: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>). Good means least risk of bias; Fair, low risk of bias; and Poor, moderate/high risk of bias.

**Including two participants with neuromyelitis optica and two with optic neuritis.

Abbreviations: pwMS, people with multiple sclerosis; HC, healthy controls; mRNA, messenger ribonucleic acid; S, spike protein; PBMC, peripheral blood mononuclear cells; IFN-g, interferon-gamma; IL, interleukin; RBD, receptor-binding domain; CLIA, chemiluminescent immunoassay; NA, not applicable; AIM, activation-induced marker; CMIA, chemiluminescence microparticle immunoassay; ECLIA, electrochemiluminescence immunoassay; AV, adenoviral vector; N, nucleocapsid protein; M-PCR, multiplex polymerase chain reaction; BBFCA, bead-based flowcytometry assay; M, membrane protein; NR, not reported; ICS, Intracellular cytokine staining; pMHC, peptide major histocompatibility complex; MNA, microneutralization assay;

607 *Table 2; Summary of Findings. Results with statistically-significant P-values are bolded.*

Factors (ref)	Post-vac outcomes							
	B-cell response		T-cell response					
	Seroconversion		IFN-g release		CD4+ AIM+		CD8+ AIM+	
	OR (95% CI)	P-value (certainty*)	OR (95% CI)	P-value (certainty*)	OR (95% CI)	P-value (certainty*)	OR (95% CI)	P-value (certainty*)
DMT (UX)								
-IFN	0.84 (0.38, 1.83)	0.66 Moderate ^{1,2}	0.02 (0.00, 0.14)	<0.01 Very Low ^{2,4,5}	Ni		Ni	
-GA	0.87 (0.31, 2.42)	0.79 Moderate ^{1,2}	Ni		NE		0.62 (0.04, 9.00)	0.72 Very Low ^{1,2,4,5}
-DMF	1.98 (0.96, 4.09)	0.07 Moderate ^{1,2}	Ni		NE		3.78 (0.18, 78.38)	0.39 Very Low ^{1,2,4,5}
-TERI	0.38 (0.16, 0.90)	0.03 Very Low ^{2,3}	Ni		Ni		Ni	
-S1PRM	0.04 (0.03, 0.06)	<0.00001 High ¹	0.04 (0.02, 0.07)	<0.00001 Low ^{1,2,3}	0.01 (0.00, 0.18)	0.001 Very Low ^{2,4,5}	0.95 (0.08, 10.71)	0.97 Very Low ^{1,2,4,5}
-NTZ	0.53 (0.24, 1.18)	0.12 Low ^{1,2,4}	1.00 (0.20, 5.12)	1.00 Very Low ^{1,2,4,5}	NE		3.95 (0.23, 69.44)	0.35 Very Low ^{1,2,4,5}
-CLAD	0.41 (0.15, 1.11)	0.08 Low ^{1,2,5}	0.01 (0.00, 0.04)	<0.00001 Low ^{1,2,5}	Ni		Ni	
-ALEM	0.32 (0.10, 0.96)	0.04 Very Low ^{2,3}	Ni		Ni		Ni	
-aCD20	0.05 (0.04, 0.06)	<0.00001 High ¹	1.12 (0.62, 2.05)	0.70 Moderate ^{1,3}	1.13 (0.17, 7.61)	0.90 Moderate ^{1,2}	2.54 (0.89, 7.27)	0.08 Moderate ^{1,5}
aCD20 infusion-to-vac (per 10 weeks)	1.94 (1.57, 2.41)	<0.00001 High ¹	Ni		Ni		Ni	

*Based on GRADE approach (Baseline: moderate due to observational nature of studies; ▲ upgrade; ▼ downgrade):
1. ▲ Result in line with quantitative analyses in individual studies; 2. ▼ Low count of studies with measurable relative effect; 3. ▼ Inconsistency; 4. ▼ Risk of missing results; and 5. ▼ Imprecision.
Abbreviations: ref, reference; vac, vaccination; IFN-g, interferon-gamma; AIM, activation-induced marker; OR, odds ratio; CI, confidence interval; DMT, disease-modifying therapy; UX, unexposed; IFN, interferons; Ni, no information; GA, glatiramer acetate; NE, not estimable; TERI, teriflunomide; S1PRM, sphingosine-1-phosphate receptor modulators; NTZ, natalizumab; CLAD, cladribine; ALEM, alemtuzumab; aCD20, anti-CD20 therapies.

608

609

Figure Legends

610 *Fig. 1; PRISMA Flow Diagram. Abbreviation: pwMS, people with multiple sclerosis.*

611 *Fig.2; Summary forest plot of the pooled results. Abbreviations: UX, unexposed; ref, reference; DMF,*
612 *dimethyl fumarate; GA, glatiramer acetate; IFN, interferons; NTZ, natalizumab; CLAD, cladribine; TERI,*
613 *teriflunomide; ALEM, alemtuzumab; aCD20, anti-CD20; S1PR, sphingosine-1-phosphate receptor*
614 *modulators; IFN-g, interferon-gamma; AIM, activation-induced marker.*

615 *Fig.3; Schematic curve showing the association of post-vaccination seroconversion rates with time since*
616 *last anti-CD20 infusion. *Current guideline recommendations on minimum delay of vaccination after anti-*
617 *CD20 infusion. Abbreviations: UX, unexposed; aCD20, anti-CD20.*

Identification of studies via databases and registers

Identification

Records identified from :
MEDLINE (n = 61)
Scopus (n = 336)
Web of Science (n = 50)
MedRxiv (n = 151)

Records removed *before screening*:
Duplicate records removed
(n = 86)

Records screened
(n = 512)

Records excluded due to
irrelevant title/abstract
(n = 482)

Reports sought for retrieval
(n = 30)

Reports not retrieved
(n = 0)

Reports assessed for eligibility
(n = 30)

Reports excluded:
No pwMS (n = 6)
No comparator (n = 3)
Case studies (n = 4)
Review study (n = 1)

Studies included in review
(n = 25)

Reports included from:
Google scholar alerts (n = 9)


Screening

Included

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.12.22270893>; this version posted February 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

B-Cells

T-Cells



Certainty

- ◆ High
- ◆ Moderate
- ◆ Low
- ◆ Very Low

**Odds of Seroconversion
(95% confidence interval)**

**Odds of positive
IFN-g release response
(95% confidence interval)**

**Odds of positive
CD4+ AIM response
(95% confidence interval)**

**Odds of positive
CD8+ AIM response
(95% confidence interval)**

